Braeburn Pharmaceuticals

BRIXADI (WEEKLY DOSING)

Manufacturer:

Braeburn Pharmaceuticals

Brixadi (Weekly Dosing) HCPCS:

J0577

HCPCS Code Descriptor:

Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy

Category:

J Code

Brixadi (Weekly Dosing) NDCs:

58284-0232-01, 58284-0224-01, 58284-0208-01, 58284-0216-01

Primary Type:

Anti-Addiction

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Brixadi (Weekly Dosing):

BRIXADI (WEEKLY DOSING) is aligned to the J Code: J0577. BRIXADI (WEEKLY DOSING) is an Anti-Addiction drug produced by Braeburn Pharmaceuticals and administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J0577 Added Date:

4/1/24

J0577 Effective Date:

4/1/24

J0577 Deactive Date:

HCPCS Active

Brixadi (Weekly Dosing) billing and coding information can be found through Braeburn Pharmaceuticals at the link below:
Brixadi (Weekly Dosing) patient assistance information can be found through Braeburn Pharmaceuticals at the URL: https://www.brixadi.com/
BRIXADI (WEEKLY DOSING) prescribing information can be found at the link below:
Our team has not yet identified a source of side effect information for BRIXADI (WEEKLY DOSING)